Considering even emmetropic eyes elongate, what are the limits of myopia control efficacy? This novel analysis explores the absolute axial elongation of treated and untreated myopes in the MiSight 3-year clinical trial in comparison to previously published models of myopic and emmetropic eye growth. The results indicate a potential limit to the short-term percentage efficacy of myopia control treatments.
Total spherical-like higher-order aberrations (HOA) increased by more than double in the distance-centred +2.50 Add compared to +1.50 Add, with total coma-like HOA increasing further. Since orthokeratology studies have reported an association between more change in HOAs and better myopia control efficacy, this could indicate a mechanism of action in multifocal contact lens myopia control.
Young adults fit with CooperVision Proclear multifocal contact lenses showed no loss of peripheral vision detection ability compared to single vision contact lenses. The near add was chosen to generate +0.50 or +1.00 of peripheral blur, confirmed by peripheral refraction measurement. This is a positive indication that fitting MFCLs in young wearers doesn’t impact peripheral visual performance.
After the 3-year MiSight 1 day clinical trial, the control group children were switched to MiSight. A ‘virtual control group’ mathematical model, previously published, was utilized to demonstrate a continued myopia control effect across six years, plus effectiveness of treatment for children who commenced wear at age 11-15 years.
The BLINK study found that +2.50 Add centre-distance multifocal contact lenses (MFCLs) slowed myopia progression but the +1.50 Add didn’t. Further analysis indicates that increased peripheral defocus created by the +2.50 Add only accounted for around 15% of the myopia control effect, indicating other mechanisms are involved.
The purpose of this 2 year study was to determine the effect of MiSight contact lenses used to control myopia on binocular vision and accommodation in children, as compared with children wearing SV spectacles, with the researches finding no significant differences in binocular and accommodative measures between the study groups.
In this review we explore the 6-year results for MiSight 1 day recently presented at the 2020 American Academy of Optometry meeting. Based on the abstract, children who were older at initial fitting (11-15 years) progressed similarly over 3 years to matched children who were treated for 6 years, indicating that older children could still gain a treatment effect from MiSight 1 day.
This 2019 study evaluated 3-year MiSight efficacy in a randomised clinical trial conducted across four different sites, in Singapore, Canada, Portugal and the UK to yield promising findings, with efficacy results comparable to previous studies, and overall high satisfaction reported by subjects. Eye Care Practitioners can utilise these results to confidently educate patients and their families on the efficacy of this treatment option.
The authors conducted a 2-year double blinded, randomised control trial to evaluate the efficacy of novel contact lens designs for myopia control. Lens I and II induced myopic defocus across a large portion of the retina, while Lens III and IV featured an extended depth of focus incorporating higher order aberrations to modulate retinal image quality. This technology is utilised in the Mark’Ennovy Mylo the and Seed 1-Day Pure EDOF lens.